Kunitoshi Iseki1, Allan J Collins2. 1. Dialysis Unit, University Hospital of the Ryukyus , Okinawa, Japan. 2. Chronic Disease Research Group, USRDS, University of Minnesota, Minneapolis, Minnesota, USA.
This issue of the Kidney International Supplements contains parts of the
proceedings of the 59th Japanese Society for Dialysis Therapy (JSDT) meeting that
took place in Kobe, Japan on 13–15 June 2014 (President: Yoshiharu
Tsubakihara). The annual JSDT meeting is an academic landmark for the society, and
it provided an opportunity for learning about advances in dialysis medicine and
exchanging experiences throughout Japan. In 2014, there were >18,000 attendees
and 3449 abstracts.The annual report on the current status of chronic dialysis therapy in Japan has been
provided by the Committee of Renal Data Registry of JSDT.[1] It was made possible with a collaboration of >4000
facilities. A news flash version is reported at each meeting. At the 2013 JSDT
meeting, ‘Recent advances in chronic kidney disease-mineral and bone disorder
research' was reported.[2]This issue of Kidney International Supplements is based on the symposium at
the 59th JSDT meeting. At the symposium, experts from several countries, including
JSDT, discussed the demographics and problems of the dialysis registry. We hope that
this supplement will help clinicians and researchers find ideas for improving
quality of life and outcomes of dialysis patients. The dialysis patient population
is expected to increase in Asian countries and in other developing countries.In addition, we asked Dr N Hanafusa to write general features of the JSDT registry.
Prevalence of chronic dialysis patients is still increasing and was 2468.1 per
million population in 2013. In Japan, prevalence is ~1 per 400 population. Mean age
is also increasing and was 67.2 years in 2013.Outcomes for Japanese dialysis patients are the best in the world.[3] However, much room for improvement remains in
dialysis regimens and medical treatments, as the prognosis is still much worse than
for the general population. Further, the socio-economic burden is an important issue
to be discussed openly.[4]
Authors: David A Goodkin; Jennifer L Bragg-Gresham; Karl G Koenig; Robert A Wolfe; Takashi Akiba; Vittorio E Andreucci; Akira Saito; Hugh C Rayner; Kiyoshi Kurokawa; Friedrich K Port; Philip J Held; Eric W Young Journal: J Am Soc Nephrol Date: 2003-12 Impact factor: 10.121